Stimulation of the antiviral innate immune response by pyrimidine biosynthesis inhibitors: A surprise of phenotypic screening;Activation de la réponse inneé antivirale par des inhibiteurs de la biosynthèse des pyrimidines

Medecine/Sciences

Volumn 31, Issue 1, 2015, Pages 98-104

  Vidalain, Pierre Olivier ^a   Lucas Hourani, Marianne ^a   Helynck, Olivier ^b   Tangy, Frédéric ^a   Munier Lehmann, Hélène ^b  

^a Institut Pasteur   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C VIRUS; RNA VIRUSES;

ANTIVIRUS AGENT; DIHYDROOROTATE DEHYDROGENASE; ENZYME INHIBITOR; MOLECULAR LIBRARY; OXIDOREDUCTASE; PYRIMIDINE; PYRIMIDINE DERIVATIVE;

ANALYSIS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; ISOLATION AND PURIFICATION; MOLECULAR LIBRARY; PHENOTYPE; VIRUS;

ANTIVIRAL AGENTS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMMUNITY, INNATE; OXIDOREDUCTASES ACTING ON CH-CH GROUP DONORS; PHENOTYPE; PYRIMIDINES; SMALL MOLECULE LIBRARIES; VIRUSES;

EID: 84922659357     PISSN: 07670974     EISSN: 19585381     Source Type: Journal    
DOI: 10.1051/medsci/20153101019     Document Type: Review

References (27)

1. Debing Y, Jochmans D, Neyts J. Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol 2013; 3 : 217-24.
2. Antona D, Baudon C, Freymuth F, et al. La rougeole en France. Med Sci (Paris) 2012; 28 : 1003-7.
3. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375 : 1545-55.
4. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 2013; 11 : 836-48.
5. International ASSWGoHIVC, Deeks SG, Autran B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12 : 607-14.
6. Pockros PJ. Advances in newly developing therapy for chronic hepatitis C virus infection. Front Med 2014; 8 : 166-74.
7. Pol S. Virus de l'hatite C. 25 ans, la fin de l'histoire Med Sci (Paris) 2013; 29 : 998-1003.
8. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014; 508 : 402-5.
9. Ison MG. Antivirals and resistance: influenza virus. Curr Opin Virol 2011; 1 : 563-73.
10. Prussia A, Thepchatri P, Snyder JP, Plemper RK. Systematic approaches towards the development of host-directed antiviral therapeutics. Int J Mol Sci 2011; 12 : 4027-52.
11. Es-Saad S, Tremblay N, Baril M, Lamarre D. Regulators of innate immunity as novel targets for panviral therapeutics. Curr Opin Virol 2012; 2 : 622-8.
12. Lucas-Hourani M, Munier-Lehmann H, Helynck O, et al. High-throughput screening for broad-spectrum chemical inhibitors of RNA viruses. J Vis Exp 2014; 87 : e51222.
13. MacMicking JD. Interferon-inducible effector mechanisms in cellautonomous immunity. Nat Rev Immunol 2012; 12 : 367-82.
14. Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011; 3 : 920-40.
15. Lucas-Hourani M, Dauzonne D, Jorda P, et al. Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog 2013; 9 : e1003678.
16. Bedard KM, Wang ML, Proll SC, et al. Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses. J Virol 2012; 86 : 7334-44.
17. Tai ZF, Zhang GL, Wang F. Identification of small molecule activators of the janus kinase/signal transducer and activator of transcription pathway using a cell-based screen. Biol Pharm Bull 2012; 35 : 65-71.
18. Patel DA, Patel AC, Nolan WC, et al. High throughput screening for small molecule enhancers of the interferon signaling pathway to drive nextgeneration antiviral drug discovery. PLoS One 2012; 7 : e36594.
19. Bonavia A, Franti M, Pusateri Keaney E, et al. Identification of broadspectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV). Proc Natl Acad Sci USA 2011; 108 : 6739-44.
20. Wang QY, Bushell S, Qing M, et al. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol 2011; 85 : 6548-56.
21. Hoffmann HH, Kunz A, Simon VA, et al. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci USA 2011; 108 : 5777-82.
22. Smee DF, Hurst BL, Day CW. D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antivir Chem Chemother 2012; 22 : 263-72.
23. Munier-Lehmann H, Vidalain PO, Tangy F, Janin YL. On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem 2013; 56 : 3148-67.
24. Liu S, Neidhardt EA, Grossman TH, et al. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure 2000; 8 : 25-33.
25. Ortiz-Riano E, Ngo N, Devito S, et al. Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor. J Virol 2014; 88 : 878-89.
26. Marschall M, Niemann I, Kosulin K, et al. Assessment of drug candidates for broad-spectrum antiviral therapy targeting cellular pyrimidine biosynthesis. Antiviral Res 2013; 100 : 640-8
27. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening Assays. J Biomol Screen 1999; 4 : 67-73.